Lipisafe F Tablet contains a combination of Atorvastatin 10 mg and Fenofibrate 160 mg, formulated to manage dyslipidemia and reduce cardiovascular risk in patients with mixed lipid disorders. Atorvastatin, a selective HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C), total cholesterol, and triglycerides while modestly increasing high-density lipoprotein cholesterol (HDL-C). Fenofibrate, a fibric acid derivative, primarily reduces serum triglycerides and increases HDL-C by activating peroxisome proliferator-activated receptors (PPARs), which enhance lipolysis and elimination of triglyceride-rich particles. The combination therapy is indicated for patients who require additional lipid control beyond monotherapy, particularly those with persistent hypertriglyceridemia and elevated LDL-C levels despite diet and lifestyle modifications. Lipisafe F should be used under medical supervision, with regular monitoring of liver function tests, renal parameters, and creatine kinase levels to detect potential adverse effects such as hepatotoxicity, myopathy, or rhabdomyolysis. Contraindications include active liver disease, severe renal impairment, and hypersensitivity to either component. Patients are advised to maintain adherence to prescribed dosage and report any unexplained muscle pain or weakness promptly. Lipisafe F Tablet offers a comprehensive lipid-lowering approach to reduce the risk of atherosclerotic cardiovascular events in appropriate patient populations.